These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

630 related articles for article (PubMed ID: 24735613)

  • 1. Current race in the development of DAAs (direct-acting antivirals) against HCV.
    De Clercq E
    Biochem Pharmacol; 2014 Jun; 89(4):441-52. PubMed ID: 24735613
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dancing with chemical formulae of antivirals: A panoramic view (Part 2).
    De Clercq E
    Biochem Pharmacol; 2013 Nov; 86(10):1397-410. PubMed ID: 24070654
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Resistance mutations against HCV protease inhibitors and antiviral drug design.
    Shang L; Lin K; Yin Z
    Curr Pharm Des; 2014; 20(5):694-703. PubMed ID: 23688081
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [RESISTANCE OF HCV TO NEW DIRECT ACTING ANTIVIRALS].
    Gozlan Y; Mendelson E; Ben-Ari Z; Mor O
    Harefuah; 2015 Nov; 154(11):684-7, 743. PubMed ID: 26821497
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emerging therapies for hepatitis C.
    Kim DY; Ahn SH; Han KH
    Gut Liver; 2014 Sep; 8(5):471-9. PubMed ID: 25228970
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatitis C treatment: an incipient therapeutic revolution.
    deLemos AS; Chung RT
    Trends Mol Med; 2014 Jun; 20(6):315-21. PubMed ID: 24636306
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of antiviral drugs for the treatment of hepatitis C at an accelerating pace.
    De Clercq E
    Rev Med Virol; 2015 Jul; 25(4):254-67. PubMed ID: 26043288
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Faldaprevir for the treatment of hepatitis C.
    Kanda T; Yokosuka O; Omata M
    Int J Mol Sci; 2015 Mar; 16(3):4985-96. PubMed ID: 25749475
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatitis C virus NS5A inhibitors and drug resistance mutations.
    Nakamoto S; Kanda T; Wu S; Shirasawa H; Yokosuka O
    World J Gastroenterol; 2014 Mar; 20(11):2902-12. PubMed ID: 24659881
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of hepatitis C virus (HCV) quasispecies dynamics upon short-term dual therapy with the HCV NS5B nucleoside polymerase inhibitor mericitabine and the NS3/4 protease inhibitor danoprevir.
    Le Pogam S; Yan JM; Chhabra M; Ilnicka M; Kang H; Kosaka A; Ali S; Chin DJ; Shulman NS; Smith P; Klumpp K; Nájera I
    Antimicrob Agents Chemother; 2012 Nov; 56(11):5494-502. PubMed ID: 22869576
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Understanding the molecular targets for new therapeutical agents in hepatitis c infection.
    Vagu C; Sultana C; Ruţă S
    Roum Arch Microbiol Immunol; 2013; 72(1):5-24. PubMed ID: 23947011
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changing the face of hepatitis C management - the design and development of sofosbuvir.
    Noell BC; Besur SV; deLemos AS
    Drug Des Devel Ther; 2015; 9():2367-74. PubMed ID: 25987834
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advances in and the future of treatments for hepatitis C.
    Cheng R; Tu T; Shackel N; McCaughan GW
    Expert Rev Gastroenterol Hepatol; 2014 Aug; 8(6):633-47. PubMed ID: 24846594
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Direct-acting and host-targeting HCV inhibitors: current and future directions.
    Chatel-Chaix L; Germain MA; Götte M; Lamarre D
    Curr Opin Virol; 2012 Oct; 2(5):588-98. PubMed ID: 22959589
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Significance of hepatitis C virus baseline polymorphism during the antiviral therapy].
    Tornai I
    Orv Hetil; 2015 May; 156(21):849-54. PubMed ID: 26038992
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New hepatitis C virus (HCV) drugs and the hope for a cure: concepts in anti-HCV drug development.
    Pawlotsky JM
    Semin Liver Dis; 2014 Feb; 34(1):22-9. PubMed ID: 24782255
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantifying antiviral activity optimizes drug combinations against hepatitis C virus infection.
    Koizumi Y; Ohashi H; Nakajima S; Tanaka Y; Wakita T; Perelson AS; Iwami S; Watashi K
    Proc Natl Acad Sci U S A; 2017 Feb; 114(8):1922-1927. PubMed ID: 28174263
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A profiling study of a newly developed HCVcc strain PR63cc's sensitivity to direct-acting antivirals.
    Tao W; Gan T; Lu J; Zhong J
    Antiviral Res; 2017 Mar; 139():18-24. PubMed ID: 28025084
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New antiviral therapies in the management of HCV infection.
    Farnik H; Zeuzem S
    Antivir Ther; 2012; 17(5):771-83. PubMed ID: 22626842
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatitis C virus resistance to protease inhibitors.
    Halfon P; Locarnini S
    J Hepatol; 2011 Jul; 55(1):192-206. PubMed ID: 21284949
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.